A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants

Sanofi

Status and phase: Completed; Phase 3

Conditions: Poliomyelitis; Diphtheria; Whooping Cough; Hepatitis B; Tetanus

Treatments: Biological: DTaP-IPV-Hep B-PRP-T Vaccine; Biological: DTaP-Hep B-IPV vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT01177722

A3L24

UTN: U1111-1111-5801 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to generate immunogenicity and safety data of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine compared to a control vaccine, Infanrix hexa™ when given along with Prevenar™ and Rotarix™ vaccines.

Primary Objectives:

• To demonstrate the equivalence of immunogenicity of 3 lots of DTaP-IPV-Hep B-PRP-T vaccine 1 month after a 3-dose primary series (2, 4 and 6 months) when given with Prevenar™ and Rotarix™, in terms of immunoresponses.
• To demonstrate the non-inferiority of the hexavalent DTaP-IPV-Hep B-PRP-T vaccine to the licensed hexavalent Infanrix hexa vaccine when given with Prevenar™ and Rotarix™.

Secondary Objectives:

• To describe in each group the immunogenicity parameters for all antigens for each vaccine
• To assess the safety profile in terms of solicited and unsolicited adverse events and serious adverse events in each group for each vaccine.

Full description

Each participant will receive 3 doses of 1 of 3 lots of the investigational hexavalent vaccine or the control vaccine, Infanrix hexa™, administered with Prevenar™ at 2, 4, and 6 months of age and Rotarix™ at 2 and 4 months of age.

All participants will be monitored for safety for 6 months after the last injection of the primary vaccination series.

Enrollment: 1,375 patients

Sex: All

Ages: 55 to 65 days old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria :

• Two month old infants (55 to 65 days old) on the day of inclusion.
• Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg.
• Informed consent form signed by one or both parents or by the legally acceptable representative as per local requirements.
• Able to attend all scheduled visits and to comply with all trial procedures.
• Received Hepatitis B and Bacille de Calmette-Guérin (BCG) vaccines between birth and one month of life in agreement with the national immunization calendar.

Exclusion Criteria :

• Participation in another clinical trial in the 4 weeks preceding the first trial vaccination.
• Planned participation in another clinical trial during the present trial period.
• Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy, or long-term systemic corticosteroid therapy.
• Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances.
• Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.
• Blood or blood-derived products received since birth that might interfere with the assessment of the immune response.
• Any vaccination before trial vaccination (except Hepatitis B and Bacille de Calmette Guérin given at birth).
• Any planned vaccination until 1 month after the last trial vaccination (except the study vaccines, rotavirus and pneumococcal conjugated vaccines).
• Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or Hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically).
• Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or Haemophilus influenzae type b infections.
• Known personal or maternal history of Human Immunodeficiency Virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C seropositivity.
• Known coagulopathy, thrombocytopenia or a bleeding disorder preceding inclusion contraindicating intramuscular (IM) vaccination.
• History of seizures or encephalopathy.
• Febrile illness (temperature ≥ 38.0°C), or moderate or severe acute illness/infection on the day of inclusion, according to the Investigator judgment.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,375 participants in 4 patient groups

Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)

Experimental group

Treatment:

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)

Experimental group

Treatment:

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)

Experimental group

Treatment:

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Biological: DTaP-IPV-Hep B-PRP-T Vaccine

Group 4: Active Control

Active Comparator group

Treatment:

Biological: DTaP-Hep B-IPV vaccine